That's the "GIST" of it: Use of adjuvant imatinib after resection of a primary GI stromal tumor Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzamides
  • Gastrectomy
  • Gastrointestinal Stromal Tumors
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Stomach Neoplasms

abstract

  • A 48-year-old man presented to his gastroenterologist with complaints of progressive dysphagia. The patient underwent an endoscopy that revealed a mass arising from the gastric fundus. Biopsies of the mass indicated an epithelioid tumor suggestive of a primary GI stromal sarcoma (GIST). A preoperative staging computed tomography/positron emission tomography scan disclosed a positron emission tomography-avid lesion in the stomach without sites of distant metastases. The patient underwent partial gastric resection with removal of a 7.8-cm primary GIST (Fig 1A) with 10 mitoses per 50 high-power fields (HPFs) that was negative for the kit protein (CD117). Mutational studies confirmed that the tumor was wild-type for c-kit but was also negative for PDGFRA and BRAF mutations. The patient presented for a discussion of adjuvant therapy. © 2014 by American Society of Clinical Oncology.

publication date

  • May 20, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.53.5971

PubMed ID

  • 24638004

Additional Document Info

start page

  • 1543

end page

  • 6

volume

  • 32

number

  • 15